NurExone Biologic Inc News - J90

NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit

TORONTO and HAIFA, Israel, March 01, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany:...

NurExone’s Intellectual Property Portfolio Expands

TORONTO and HAIFA, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany:...

NurExone Launches Licensing Efforts for ExoTherapy Platform

TORONTO and HAIFA, Israel, Feb. 14, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany:...

Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant

TORONTO and HAIFA, Israel, Feb. 02, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90...

NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market

TORONTO and HAIFA, Israel, Jan. 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90...

NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million

TORONTO and HAIFA, Israel , Jan. 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90...

NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration

TORONTO and HAIFA, Israel, Nov. 29, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90...

NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update

TORONTO and HAIFA, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90...

NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment

TORONTO and HAIFA, Israel, Oct. 30, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90...

Appointment of Professor Teo Forcht Dagi to Scientific Advisory Board and Advisory Committee

TORONTO and HAIFA, Israel, Oct. 19, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90...

NurExone Secures Eureka Grant for Collaborative Partnership to Expand to Chronic Spinal Cord Injury Therapy

TORONTO and HAIFA, Israel, Oct. 11, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90...

NurExone Biologic to Present Exosome-Based Therapy for Spinal Cord Injury in Regenerative Medicine Session at Upcoming Extracellular Vesicles Forum

TORONTO and HAIFA, Israel, Oct. 05, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90...

NurExone Appoints Dr. Reuter Investor Relations in Europe

TORONTO and HAIFA, Israel, Sept. 28, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90...

NurExone Moves Forward Towards Human Clinical Trials, Completes Pre-IND Meeting with the FDA for Proprietary ExoPTEN Drug

The FDA’s response indicated that the planned toxicity study strategy is acceptable under FDA guidelines and...

NurExone Announces Closing of Second Tranche of Private Placement, bringing total raise at this round to approximately CAD$1.5M

TORONTO and HAIFA, Israel, Sept. 06, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

NurExone Biologic Inc (J90)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

J90 News

NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit

NurExone’s Intellectual Property Portfolio Expands

NurExone Launches Licensing Efforts for ExoTherapy Platform

Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant

NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market

NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million

NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration

NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update

NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment

Appointment of Professor Teo Forcht Dagi to Scientific Advisory Board and Advisory Committee

NurExone Secures Eureka Grant for Collaborative Partnership to Expand to Chronic Spinal Cord Injury Therapy

NurExone Biologic to Present Exosome-Based Therapy for Spinal Cord Injury in Regenerative Medicine Session at Upcoming Extracellular Vesicles Forum

NurExone Appoints Dr. Reuter Investor Relations in Europe

NurExone Moves Forward Towards Human Clinical Trials, Completes Pre-IND Meeting with the FDA for Proprietary ExoPTEN Drug

NurExone Announces Closing of Second Tranche of Private Placement, bringing total raise at this round to approximately CAD$1.5M

J90 Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

NurExone Biologic Inc (J90) News

NurExone Biologic Inc (J90)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

J90 News

NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit

NurExone’s Intellectual Property Portfolio Expands

NurExone Launches Licensing Efforts for ExoTherapy Platform

Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant

NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market

NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million

NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration

NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update

NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment

Appointment of Professor Teo Forcht Dagi to Scientific Advisory Board and Advisory Committee

NurExone Secures Eureka Grant for Collaborative Partnership to Expand to Chronic Spinal Cord Injury Therapy

NurExone Biologic to Present Exosome-Based Therapy for Spinal Cord Injury in Regenerative Medicine Session at Upcoming Extracellular Vesicles Forum

NurExone Appoints Dr. Reuter Investor Relations in Europe

NurExone Moves Forward Towards Human Clinical Trials, Completes Pre-IND Meeting with the FDA for Proprietary ExoPTEN Drug

NurExone Announces Closing of Second Tranche of Private Placement, bringing total raise at this round to approximately CAD$1.5M

J90 Discussion

Your Recent History